Review outlines PKD1 dosage regulation and anti-miR-17 therapy in ADPKD

The review examines how PKD1 gene architecture, RNA processing, protein maturation and untranslated regions influence functional polycystin-1 levels in ADPKD. The authors focus on the hypothesis that insufficient polycystin-1 dosage contributes to cyst formation and that regulation of residual PKD1 output may be therapeutically relevant.

The article describes conserved microRNA-binding sites in the PKD1 3′ untranslated region, including a miR-17 site. It reports that genetic disruption or pharmacologic inhibition of miR-17 increases polycystin dosage and attenuates cystic disease in experimental models. The source also states that early clinical pharmacodynamic findings with the anti-miR-17 oligonucleotide farabursen are consistent with increased polycystin-1 and polycystin-2 derepression, and that the drug is advancing into Phase 3 development.

These findings support further study of transcript derepression as a potential mutation-agnostic approach, but the review does not establish clinical benefit or support a change in current care. The supplied text gives no trial size, clinical outcome results, or sponsor details; it also notes that the text is machine generated and may contain inaccuracies.